These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 12967599)

  • 1. Increased excretion of urine coproporphyrins during daunorubicin administration in patients affected by acute myelogenous leukemia.
    Pinelli A; Mussini C; Bertolini B; Buratti M; Trivulzio S
    Pharmacol Res; 2003 Nov; 48(5):515-8. PubMed ID: 12967599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daunorubicine in acute myelogenous leukemia in adults.
    Bornstein RS; Theologides A; Kennedy BJ
    JAMA; 1969 Feb; 207(7):1301-6. PubMed ID: 5250070
    [No Abstract]   [Full Text] [Related]  

  • 3. Similar incidence of typhlitis in patients receiving various doses of daunorubicin or idarubicin as induction for acute myeloid leukemia.
    Seddon AN; Chaim J; Akin O; Drill E; Michael AG; Adel N; Tallman MS
    Leuk Res; 2018 May; 68():48-50. PubMed ID: 29544131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased urinary coproporphyrin excretion observed in patients with differently staged Hodgkin's disease treated with chemotherapy.
    Pinelli A; Mussini C; Buratti M; Parmiggiani-Venezia M; Trivulzio S
    Pharmacol Res; 2005 Mar; 51(3):283-8. PubMed ID: 15661580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The anemias, with particular reference to classification and to alterations in the erythrocyte protoporphyrin and urinary coproporphyrin.
    WATSON CJ
    Bol Asoc Med P R; 1948 Feb; 40(2):43-7. PubMed ID: 18916044
    [No Abstract]   [Full Text] [Related]  

  • 6. Administration schedule of daunorubicin for elderly patients with acute myelogenous leukemia: a single-institute experience.
    Dobashi N; Usui N; Yano S; Yahagi Y; Takei Y; Sugiyama K; Takahara S; Ogasawara Y; Yamaguchi Y; Saito T; Yokoyama H; Aiba K
    Jpn J Clin Oncol; 2011 Jun; 41(6):820-4. PubMed ID: 21415001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy-induced acral erythema in leukemic patients: a report of 15 cases.
    Demirçay Z; Gürbüz O; Alpdoğan TB; Yücelten D; Alpdoğan O; Kurtkaya O; Bayik M
    Int J Dermatol; 1997 Aug; 36(8):593-8. PubMed ID: 9329890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of daunorubicin in the induction therapy for adult acute myeloid leukemia.
    Usui N; Dobashi N; Kobayashi T; Yano S; Maki N; Asai O; Saito T; Yamaguchi Y; Watanabe H; Kato A; Ogihara A; Katori M; Nagamine M; Takei Y; Yamazaki H; Funakoshi S; Tajima N; Ogawa M; Kuraishi Y
    J Clin Oncol; 1998 Jun; 16(6):2086-92. PubMed ID: 9626208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose versus standard-dose daunorubicin in induction therapy for young patients with de novo acute myeloid leukaemia: a meta-analysis of randomised trials.
    Su L; Zhu X; Gao S; Li W; Liu X; Tan Y
    J Chemother; 2016 Apr; 28(2):123-8. PubMed ID: 27104964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generalized hyperpigmentation with daunorubicin chemotherapy.
    Kroumpouzos G; Travers R; Allan A
    J Am Acad Dermatol; 2002 Feb; 46(2 Suppl Case Reports):S1-3. PubMed ID: 11807454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daunorubicin-induced hyperpigmentation.
    Pol RR; Wright A; Hill A
    Br J Haematol; 2010 Dec; 151(5):414. PubMed ID: 21029070
    [No Abstract]   [Full Text] [Related]  

  • 12. Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia.
    Russo D; Piccaluga PP; Michieli M; Michelutti T; Visani G; Gugliotta L; Bonini A; Pierri I; Gobbi M; Tiribelli M; Fanin R; Piccolrovazzi S; Baccarani M
    Ann Hematol; 2002 Aug; 81(8):462-6. PubMed ID: 12224004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of 60 or 90 mg/m(2) of daunorubicin in induction therapy for acute myeloid leukemia with intermediate or unfavorable cytogenetics.
    Devillier R; Bertoli S; Prébet T; Huguet F; Etienne A; Charbonnier A; Rey J; Delabesse E; D'Incan E; Huynh A; Blaise D; Récher C; Vey N
    Am J Hematol; 2015 Feb; 90(2):E29-30. PubMed ID: 25363834
    [No Abstract]   [Full Text] [Related]  

  • 14. [Rubidomycin in the treatment of leukemias in children (preliminary clinical observation)].
    Zinkiewicz Z; Wróblewska B
    Wiad Lek; 1969 Jan; 22(2):155-8. PubMed ID: 5252540
    [No Abstract]   [Full Text] [Related]  

  • 15. Pharmacokinetics of erythrocyte-bound daunorubicin in patients with acute leukemia.
    Skorokhod OA; Garmaeva TTs; Vitvitsky VM; Isaev VG; Parovichnikova EN; Savchenko VG; Ataullakhanov FI
    Med Sci Monit; 2004 Apr; 10(4):PI55-64. PubMed ID: 15039656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daunorubicin 90 mg/m
    Portugal R; Lyrio R; Loureiro M; Urago K; Bard J; Borchardt A; Garnica M; Nucci M
    Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):527-531. PubMed ID: 28842139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transverse leukonychia (Mees' lines) due to daunorubicin chemotherapy.
    Shelley WB; Humphrey GB
    Pediatr Dermatol; 1997; 14(2):144-5. PubMed ID: 9144702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequencing of cytosine arabinoside (NSC-63878) and daunorubicin (NSC-82151) in acute myelogenous leukemia.
    Omura GA
    Cancer Treat Rep; 1976 May; 60(5):629-31. PubMed ID: 1068745
    [No Abstract]   [Full Text] [Related]  

  • 19. Single-nucleotide polymorphisms in reductase genes are not associated with response to daunorubicin-based remission induction.
    Lubieniecka JM; Liu J; Graham J; Heffner D; Reid R; Hogge D; Grigliatti TA; Riggs WK
    Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1918-20. PubMed ID: 23880735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher plasma but not intracellular concentrations after infusion with liposomal daunorubicin compared with conventional daunorubicin in adult acute myeloid leukemia.
    Löfgren C; Lehmann S; Jönsson-Videsäter K; Möllgård L; Linder O; Tidefelt U; Hassan M; Paul C
    Ther Drug Monit; 2007 Oct; 29(5):626-31. PubMed ID: 17898654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.